Pink SheetEisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the ear
ScripEisai plans to launch Leqembi (lecanemab) in Germany and Austria in fiscal year 2025 and will stagger the drug’s launch in other EU countries over the next few years, following the approval of the ear
ScripBristol Myers Squibb obtained two US Food and Drug Administration approvals during the week of 7 April for combination therapy with its immuno-oncology stalwarts Opdivo (nivolumab) and Yervoy (ipilimu
ScripThe number of drug candidates in the pipeline in 2024 rose by its lowest rate so far this decade, with the total at the turn of the year hitting 23,875. The 4.60% increase over 2024’s pipeline figure